Interaction in Chronic Obstructive Pulmonary Disease Experiment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-09-30

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The final purpose of this study is to determine whether bronchodilation and cigarette smoking in Chronic Obstructive Pulmonary Disease (COPD) patients interact, resulting in an increase of cardiovascular disease. The aim of this part of the study is to demonstrate the basic mechanism: Does increased respiratory function after administration of a bronchodilator in patients with COPD lead to elevated pulmonary retention of the harmful compounds in inhaled cigarette smoke and to short-term biological effects associated with cardiovascular disease?

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Dual Bronchodilator Treatment on Cardiopulmonary Interactions in COPD

NCT03425617

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE4

To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways

NCT02085161

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE3

Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation

NCT00578968

Chronic Obstructive Pulmonary Disease COPD

COMPLETED PHASE4

Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)

NCT00139932

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE4

Bronchodilators and Respiratory Mechanics in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT00783250

Chronic Obstructive Pulmonary Disease

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

COPD currently is one of the most frequent diseases. In more than 80% of COPD patients, the disease is caused by smoking. About half of the COPD patients are active smokers, although smoking is also the most important prognostic factor. Also, smoking is an important cause as well as an important prognostic factor in cardiovascular disease. The corner stone of medical treatment in COPD is bronchodilation; more than half of the patients use a long-acting bronchodilator. An increase of the pathogenic effect of smoking by an increased lung function after bronchodilation is likely though, since more pathogenic particles would penetrate the lung. We hypothesize that bronchodilators increase cardiovascular disease in COPD patients who smoke.

In order to demonstrate the basic mechanism of our hypothesis, COPD patients receive a bronchodilator at one time and a placebo at another time, preceded and followed by cigarette smoking during one hour as by a strict time schedule. Smoke retention, lung function and blood biomarkers are repeatedly measured.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease Cardiovascular Disease Smoking Bronchodilation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

beta 2 agonist + anticholinergic aerosol

Group Type ACTIVE_COMPARATOR

Tiotropium (Spiriva) + Salbutamol (Ventolin)

Intervention Type DRUG

1 time inhalation of 5 mcg of Tiotropium bromide by Respimat and 400 mcg of Salbutamol by Volume Spacer. cigarette smoking

placebo inhalation

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

1 time inhalation of placebo with the amount of puffs similar to the active comparator. cigarette smoking

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tiotropium (Spiriva) + Salbutamol (Ventolin)

1 time inhalation of 5 mcg of Tiotropium bromide by Respimat and 400 mcg of Salbutamol by Volume Spacer. cigarette smoking

Intervention Type DRUG

placebo

1 time inhalation of placebo with the amount of puffs similar to the active comparator. cigarette smoking

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Spiriva Respimat Ventolin Aerosol Ventolin placebo and Spiriva placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* COPD Gold stage II-III (FEV1/FVC\<0,70 and FEV1 30-80% of predicted value).
* Current cigarette smoking (at the time of performing the study).
* Willing to provide written informed consent.
* Refrain from smoking and bronchodilators \> 8 hours (depends on treatment) before the test.
* Registered in one of the recruitment institutes.

Exclusion Criteria

* COPD gold stage I or IV.
* Asthmatic component: History of asthma, present asthma by complaints, eosinophilia or reversibility ≥ 10% of predicted.
* Unable to communicate.
* Physically unable to perform any of the tests.
* Non-COPD respiratory disorders.
* Previous lung-volume reduction surgery and/or lung transplantation.
* Evidence of alcohol, drug or solvent abuse.
* Known α-1 antitrypsin deficiency.

Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No